http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Shin Myung Kang,Moo Suk Park,Joon Chang,Haeryoung Kim,Dong-Hwan Shin,Se Kyu Kim,Kyung Young Chung,Dae Joon Kim,Joo Hyuk Sohn,최성호,Jeongmi Kim,Eun Jin Yoon,Joo-Hang Kim 대한암학회 2005 Cancer Research and Treatment Vol.37 No.4
Purpose: A chemosensitivity test can reflect the differences in responses of individual cancer patients to chemotherapeutic agents. The adenosine triphosphatebasedchemotherapy response assay (ATP-CRA)is an accurate method, which does not require a large amount of tissue specimen. So far, no studies have evaluated the utility of the ATP-CRA in Korea. Therefore, we investigated the clinical usefulness of the ATP-CRA in 53 patients with lung cancer.Materials and Methods: Tumor tissues were obtained from bronchoscopic biopsies or surgical resections. The validity of ATP-CRA was assessed focusing on the success rate, experimental error level (intraassay mean coefficient of variation [CV]) and reproducibility.Results: The overall success rate of ATP-CRA was 90.6% (48/53). Normal cells were effectively eliminated from the tumor tissues with the use of ficoll gradient centrifugation and immunomagnetic separation, which was confirmed using loss of heterozygosity analysis of the 3p deletion. The mean CV of ATP assays was 10.5± 4.6%. The reproducibility of ATP assays was 94±3.8%. The results of the ATP assays were reported to physicians within 7 days of specimen collection. More than 6 anticancer drugs were tested on the tumor specimens obtained from bronchoscopic biopsies.Conclusion: The ATP-CRA is a stable, accurate and potentially practical chemosensitivity test in patients with lung cancer.
Hepatic hemangioma: proportion and predictor of surgical treatment with emphasis on its growth rate
Young Cheol Shin,Eun Ju Cho,Hee Young Na,Jai Young Cho,Ho-Seong Han,Yoon Jin Lee,Haeryoung Kim,sangmi jang,Gwang Hyeon Choi,Eun Sun Jang,Jin-Wook Kim,Sook-Hyang Jeong 대한내과학회 2023 The Korean Journal of Internal Medicine Vol.38 No.6
Background/Aims: There are limited studies on the management of hepatic hemangiomas (HHs). We investigated the proportion and predictors of surgical resection and analyzed HH growth rates in addition to associated factors. Methods: A retrospective case-control study of patients treated in 2 centers was conducted. Thirty-six patients who underwent surgical resection were assigned to the case group. Patients who did not undergo surgical treatment were randomly sigselected at a 1:10 ratio and assigned to the control group (n = 360). Baseline characteristics, clinical course and surgical outcomes were analyzed. Results: The proportion of surgically treated HH patients was 0.3% (36 per 11,049). The longest diameter at diagnosis (mean ± standard deviation) was 7.7 ± 5.2 cm in the case group and 2.4 ± 1.8 cm in the control group (p < 0.001). In the multivariate analysis, the presence of more than 2 HHs (odds ratio [OR] 7.64, 95% confidence interval [CI] 1.40–41.72) and a growth rate of more than 4.8%/year (OR 30.73, 95% CI 4.86–194.51) were independently associated with surgical treatment. Symptom development during follow-up was related to HH size > 10 cm (OR 10.50, 95% CI 1.06–103.77, p = 0.04). The subgroup analysis showed substantial growth in 41.3% with an overall mean annual growth rate of 0.14 cm. Conclusions: Approximately one in 300 patients with an HH underwent surgical treatment. Multiple HHs and a growth rate of more than 4.8%/year were indications for surgical treatment. Nearly half of the HHs showed growing pattern in our study.
( Sukho Hong ),( Eun Shin ),( Haeryoung Kim ),( Ho Seong Han ),( Jai Young Cho ),( Yoo Seok Yoon ),( Sang Soo Lee ),( Jung Wha Chung ),( Sung Wook Yang ),( Seong Min Chung ),( Eun Sun Jang ),( Jin Woo 대한간학회 2013 춘·추계 학술대회 (KASL) Vol.2013 No.1
Background: Excessive accumulation of iron can result in hepatic dysfunction. However, the prevalence and related factors of iron overload in hepatocellular carcinoma (HCC) patients in hepatitis B virus prevalent region was limitedly studied. We analyzed the prevalence, cellular localization and related factors of liver iron overload using liver tissue samples obtained from HCC patients. Methods: We retrospectively enrolled 231 HCC patients who underwent surgical resection from May 2003 to Dec 2011 in Seoul National University Bundang Hospital. Hepatic iron content was measured semi-quantitatively using adjusted Duegnier`s method and simplified Sheuer method in non-tumorous liver samples The cellular localization of iron deposit was assessed by calculation of hepatocyte iron score (HIS), sinusoidal iron score (SIS) and portal iron score (PIS) , and summation of these 3 scores presented as total iron score (TIS) according to adjusted Duegnier`s method. Iron distribution at hepatocytes and kupffer cells according to Scheuer`s method was also investigated. The clinical variables related to hepatic iron overload were assessed using various cutoff of hepatic iron overload. Results: Iron deposition was found in 43% of non-tumorous tissue with mean TIS of 1.1(SD 2.0). Iron overload > TIS 2 was found in 19.0% (Deugnier`s method) with median HIS, SIS, PIS, TIS and corrected TIS was 1.7, 0.2, 0.1, 0.8 and 0.3, respectively. Hepatocyte and Kupffer cell iron deposition was found in 38 and 23%, respectively (Schuer`s method). The iron overload overload group (>TIS 2) showed significantly lower platelet count, higher MELD score, and more advanced BCLC stage. Iron overload at Kupffer cells but not at hepatocytes, was associated with mortality. Conclusions: Approximately 20% of HCC patients showed hepatic iron overload, which was related to advanced stage of liver cirrhosis or BCLC stage. Iron overload at Kupffer cells rather than at hepatocyte was associated with high mortality, which warrants further study.
Primary hepatic choriocarcinoma in a female patient
Makhmud Malikov,Eun Shin(신은),Jai Young Cho(조재영),Ho-Seong Han(한호성),You-Seok Yoon(윤유석),Young Rok Choi(최영록),Jae Yool Jang(장재율),Hanlim Choi(최한림),Jae Seong Jang(장재성),Seong Uk Kwon(권성욱),Haeryoung Kim(김혜령) 대한종양외과학회 2015 Korean Journal of Clinical Oncology Vol.11 No.1